Greenberg PE[au] - Search Results

Year	Number of Results
1993	2
1995	2
1996	1
1997	1
1998	1
1999	4
2000	1
2001	6
2002	3
2003	5
2004	1
2005	2
2006	1
2007	2
2008	3
2009	6
2010	5
2011	1
2012	1
2013	1
2014	1
2015	1
2018	1
2019	2
2020	1
2021	3
2022	1
2025	0

1

The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018).

Greenberg PE, Fournier AA, Sisitsky T, Simes M, Berman R, Koenigsberg SH, Kessler RC. Greenberg PE, et al. Pharmacoeconomics. 2021 Jun;39(6):653-665. doi: 10.1007/s40273-021-01019-4. Epub 2021 May 5. Pharmacoeconomics. 2021. PMID: 33950419 Free PMC article.

2

Introducing perspectives on comparative effectiveness research.

Birnbaum HG, Greenberg PE. Birnbaum HG, et al. Among authors: greenberg pe. Pharmacoeconomics. 2010;28(10):787-8. doi: 10.2165/11535820-000000000-00000. Pharmacoeconomics. 2010. PMID: 20831286 No abstract available.

3

Does generic substitution always make sense?

Greenberg PE. Greenberg PE. J Med Econ. 2008;11(3):547-53. doi: 10.3111/13696990802371075. J Med Econ. 2008. PMID: 19450104 Free article. No abstract available.

4

Cost of illness: an ongoing battle worth fighting.

Greenberg PE. Greenberg PE. Pharmacoeconomics. 2014 Dec;32(12):1151-2. doi: 10.1007/s40273-014-0217-z. Pharmacoeconomics. 2014. PMID: 25204852 No abstract available.

5

Introduction to the Special Issue of PharmacoEconomics on Major Depressive Disorders.

Greenberg PE, Sisitsky T. Greenberg PE, et al. Pharmacoeconomics. 2021 Jun;39(6):617. doi: 10.1007/s40273-021-01041-6. Epub 2021 May 13. Pharmacoeconomics. 2021. PMID: 33982197 Free PMC article. No abstract available.

6

Perspectives on comparative effectiveness research: views from diverse constituencies.

Nellesen D, Birnbaum HG, Greenberg PE. Nellesen D, et al. Among authors: greenberg pe. Pharmacoeconomics. 2010;28(10):789-98. doi: 10.2165/11535790-000000000-00000. Pharmacoeconomics. 2010. PMID: 20831287 No abstract available.

7

Assessing the economic impact of psychiatric disorders: where to begin?

Greenberg PE, Leong SA, Birnbaum HG. Greenberg PE, et al. Expert Opin Pharmacother. 2001 Apr;2(4):641-52. doi: 10.1517/14656566.2.4.641. Expert Opin Pharmacother. 2001. PMID: 11336613 Review.

8

Confounding factors in off-label drug use.

Greenberg PE, Pike C, Sisitsky T. Greenberg PE, et al. Health Aff (Millwood). 2012 Feb;31(2):460; author reply 460. doi: 10.1377/hlthaff.2011.1394. Health Aff (Millwood). 2012. PMID: 22323178 No abstract available.

9

The economic burden of depression in the US: societal and patient perspectives.

Greenberg PE, Birnbaum HG. Greenberg PE, et al. Expert Opin Pharmacother. 2005 Mar;6(3):369-76. doi: 10.1517/14656566.6.3.369. Expert Opin Pharmacother. 2005. PMID: 15794728 Review.

10

Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.

Kalb PE, Greenberg PE. Kalb PE, et al. Among authors: greenberg pe. Pharmacoeconomics. 2009;27(8):623-5. doi: 10.2165/11315660-000000000-00000. Pharmacoeconomics. 2009. PMID: 19835018 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year